« Return to News | Drug Sponsors

Shire shows strong profits for Q1

Tuesday, May 3, 2011 01:09 PM

Shire Pharmaceuticals has strong results for the first quarter, with its attention-deficit hyperactivity disorder (ADHD) drugs driving growth, according to Pharma Times.

Net income came in at $211.3 million, up 27%, while revenues increased 19% to $972 million. Turnover was driven by the ADHD drug Vyvanse (lisdexamfetamine dimesylate), which grew 31% to $202.3 million, and Adderall XR (mixed amphetamine salts) brought in $111.2 million, up 21%. Another ADHD drug, Intuniv (guanfacine), had sales of $41.9 million.

Shire rare diseases portfolio also fared particularly well, with Replagal (agalsidase alfa) for Fabry disease increased 55% to $105.4 million. Vpriv (velaglucerase alfa) for Gaucher's disease, brought in $59 million, up 917. The Hunter Syndrome therapy Elaprase (idursulfase) rose 3% to $103.5 million.

As for Shire's other products, Pentasa (mesalamine) climbed 11% to $64.5 million, and the firm’s newer ulcerative colitis drug Lialda/Mezavant brought in $87.1 million, up 37%.

The company also revealed positive phase II data looking at Vyvanse as a potential adjunctive treatment in for the negative symptoms of schizophrenia. Plans for a study in binge eating disorder as well as the continuing phase III program looking at Vyvanse for major depressive disorder may be underway as well.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

February 25

Analysts: With market anticipation of Quintiles IPO, other CROs could soon file to go public

National Clinical Trial Network aims to link sponsors, minority patients for trials and access to new therapies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

March

Sites rate the best
sponsors of 2013
Largest survey response ever puts Biogen Idec, Forest Labs, Bayer at top

As CRO industry
turns 30, a look back
at modest beginnings
Phenomenal growth, strategic partnering highlight evolution
of CROs

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

February

Sized out of big deals,
mid-tier CROs still thriving
Finding market niches, strategies to stay vital in changing research enterprise

Industry leaders embrace disruptive innovations
Despite resistance to change, many exploring data sharing, open-source collaboration

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.